| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5559111 | NOVARTIS | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8613949 | NOVARTIS | Galenical formulations of organic compounds |
Dec, 2029
(5 years from now) | |
Tekamlo is owned by Novartis.
Tekamlo contains Aliskiren Hemifumarate; Amlodipine Besylate.
Tekamlo has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Tekamlo are:
- US5559111
Tekamlo was authorised for market use on 26 August, 2010.
Tekamlo is available in tablet;oral dosage forms.
Tekamlo can be used as treatment of hypertension.
Drug patent challenges can be filed against Tekamlo from 06 March, 2011.
The generics of Tekamlo are possible to be released after 21 December, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
| New Combination(NC) | Aug 26, 2013 |
Drugs and Companies using
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE ingredient
NCE-1 date:
06 March, 2011
Market Authorisation Date:
26 August, 2010Treatment:
Treatment of hypertensionDosage:
TABLET;ORAL
More Information on Dosage
TEKAMLO family patents
